700835-81-0

Basic information

• Product Name: Isoxazole, 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(1-methylethyl)-
• CAS NO: 700835-81-0
• Molecular Formula: C13H12Cl3NO
• Molecular Weight: 304.603
• Mol File: 700835-81-0.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Isoxazole, 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(1-methylethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Isoxazole, 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(1-methylethyl)-(700835-81-0)
• EPA Substance Registry System: Isoxazole, 4-(chloromethyl)-3-(2,6-dichlorophenyl)-5-(1-methylethyl)-(700835-81-0)

Safety Data

• Hazardous Substances Data: 700835-81-0(Hazardous Substances Data)

Upstream product

• 278597-30-1 [3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazol-4-yl]methanol 
• 278597-28-7 methyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 6579-27-7 2,6-dichlorobenzohydroximoyl chloride 
• 25185-95-9 2,6-dichlorobenzaldoxime 
• 6575-28-6 (1E)-2,6-dichlorobenzaldehyde oxime 
• 774605-35-5 ethyl 3-(2,6-dichlorophenyl)-5-(propan-2-yl)-1,2-oxazole-4-carboxylate 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 6579-27-7 2,6-Dichloro-N-hydroxybenzenecarboximidoyl chloride 

Downstream Products

• 1097776-93-6 methyl 5-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-3-pyridinecarboxylate 
• 1097776-98-1 methyl 6-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-2-pyridinecarboxylate 
• 1097777-03-1 methyl 5-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-2-pyridinecarboxylate 
• 1097777-09-7 methyl 4-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-2-pyridinecarboxylate 
• 1097777-13-3 methyl 2-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-4-pyridinecarboxylate 
• 1097777-21-3 methyl 6-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-3-pyridinecarboxylate 
• 1097777-25-7 3-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]aniline 
• 1097777-36-0 methyl 3-[7-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]benzoate 
• 1097777-40-6 ethyl 2-chloro-5-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]benzoate 
• 1097777-45-1 methyl 5-[6-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2-naphthalenyl]-2-fluorobenzoate 
• 1097778-46-5 methyl 3-{[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-1H-indol-1-yl]methyl}benzoate 
• 1097778-35-2 methyl 3-[5-({[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl}oxy)-2,3-dihydro-1H-inden-2-yl]benzoate 
• 1268245-11-9 3-(2-(2-chloro-4-((3-(2,6-dichlorophenyl)-5-isopropylisoxazol-4-yl)methoxy)phenyl)cyclopropyl)benzoic acid 

Relevant articles and documents

Novel isoflavone derivative, preparation method therefor and medicinal use of novel isoflavone derivative

The invention relates to the field of pharmaceutical chemistry, relates to an isoflavone derivative, a preparation method therefor and medicinal use of the novel isoflavone derivative and particularlyrelates to isoflavone derivatives represented by a general formula (I) shown in the description, preparation methods therefor, pharmaceutical compositions containing these compounds and medicinal useof the isoflavone derivatives and the pharmaceutical compositions, particularly use of drugs for preventing or treating hyperlipidemia, type II diabetes, atherosclerosis and non-alcoholic fatty hepatitis.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS

The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hype

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds, and to a process for the synthesis of said compounds.